Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic Life Sciences has selected C1-INH as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of hereditary angioedema (HAE), a rare genetic disorder in which C1-INH is lacking.
Subscribe to our email newsletter
The world market for HAE reached $1.1bn in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect the market to exceed $3bn by 2020.
ProMetic has successfully completed the bioprocess to isolate and purify C1-INH, and has scheduled scale-up and GMP production to occur during the second half of 2015.
ProMetic anticipates commencement of C1-INH clinical trial work in H1 2016. C1-INH adds to a pipeline of previously disclosed proteins already scheduled for clinical development, namely: plasminogen, IVIG and alpha-1 antitrypsin.
"As anticipated, our manufacturing platform is demonstrating its ability to produce multiple high-value biopharmaceuticals simultaneously and at yield and purity levels superior to those commercially available", declared Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic.
"We will be announcing other proteins in the coming months. Some of these will be developed and marketed with commercial partners and are already, as in the case of C1-INH, in partnering discussions", added Mr. Laurin.
C1 esterase inhibitor (C1-INH) is a blood protein that controls C1, the first component of the complement system, a complex network of proteins which are important in the body’s ability to resist infection.
Congenital deficiency of C1-INH causes hereditary angioedema, Deficiency of C1-INH may rarely be acquired later in life, usually associated with white cell malignancies or autoimmune disease.